This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include:
• Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion across 1,795 deals. Aggregate value dropped between Q2 and Q3 and plateaued between Q3 and Q4 amidst prolonged global volatility.
Please see full publication below for more information.
